Tumor necrosis factor (TNF) is up-regulated in a variety of central nervous system (CNS) diseases with diverse etiology and pathologic manifestation. TNF mediates multiple biological activities through two membrane receptors, the p55 and p75 TNF receptors (TNFRs). We have shown previously that human transmembrane TNF (tmTNF)͞p55TNFR signaling in transgenic mice triggers oligodendrocyte apoptosis, endothelial cell activation, parenchymal inflammation, and primary demyelinating lesions similar to those of acute multiple sclerosis. To address the role of the p75TNFR in the CNS, we have generated ''humanized'' mice that express human tmTNF in astrocytes and a physiologically regulated human p75TNFR transgene, in the absence of the endogenous (murine) p55TNFR. Human tmTNF͞p75TNFR transgenic mice develop CNS vascular pathology, characterized by endothelial cell activation, meningeal inflammation, and vessel fibrosis. There is no evidence of oligodendrocyte apoptosis or primary demyelination in these mice. Late in disease, vasculitis can result in vessel occlusion and secondary, multifocal CNS ischemic injury. These results identify a proinflammatory role for the p75TNFR at the level of the CNS vascular endothelium, which correlates with the expression pattern of this receptor in the CNS, and indicate that the differential expression patterns of the two TNFRs within the CNS play a significant role in shaping the outcome of TNF signaling during neuroimmune interactions.
T
umor necrosis factor (TNF) is up-regulated in a variety of CNS diseases with diverse etiology and pathological manifestation such as brain trauma (1) and ischemic injury (2) , multiple sclerosis (3) , and Alzheimer's disease (4) and has been implicated in their pathogenesis. TNF mediates its multiple biological activities through two membrane receptors, the p55 and p75 TNF receptors (TNFRs). The two receptors are coexpressed in most tissues including the CNS (5, 6), but through activation of different signaling cascades they can mediate distinct cellular responses (7, 8) . The p55TNFR can signal almost all reported TNF activities including cell death and proliferation (9, 10) . In contrast, the effects of p75TNFR signaling are evident in few cell systems and include promotion of proliferative responses in thymocytes, T lymphocytes, and other cells of haemopoietic origin (11) as well as apoptotic signals in mature activated CD8 ϩ T cells (12) . The 26-kDa transmembrane (tm)TNF molecule has been shown to be superior to soluble TNF in activating the p75TNFR in various systems such as T cell activation and thymocyte proliferation (13) . Studies of TNFR knockout mice have revealed few specific functions for the p75TNFR (14, 15) . It can induce inflammation when expressed in transgenic mice (16) , is neuroprotective in experimental retinal ischemia (17) , and plays an essential role in the pathogenesis of experimental cerebral malaria (18) .
Several lines of evidence implicate the p75TNFR in the pathogenesis of human diseases. Its expression is up-regulated by lung microvascular endothelial cells in acute respiratory distress syndrome (ARDS) (19) , and both TNFRs are expressed by oligodendrocytes at the rim of active multiple sclerosis lesions (3) . TNF is produced locally by astrocytes and neurons in the CNS tissues of cerebral stroke patients (20) and is implicated in coagulation events leading to thrombosis and vascular occlusion in the dermal vessel endothelium (21) . We investigated the contribution of the p75TNFR to TNF-mediated CNS pathology in vivo and tried to determine whether the p55TNFR and p75TNFR can mediate independent and distinct biological effects. In our previous studies, overexpression of a human TNF transgene in mice allowed us to analyze the specific effects of p55TNFR-mediated signaling, because the murine (mu)p75TNFR is species-specific and unable to transmit signals from human TNF. We showed that astrocyte-specific human tmTNF͞p55TNFR signaling in the CNS of transgenic mice can induce oligodendrocyte apoptosis and acute inflammatory demyelination, and these mice provide an animal model for multiple sclerosis (22, 23) . In this report, we combined transgenic and gene-targeting technology to generate mice in which astrocyte-specific human tmTNF signals exclusively through a correctly regulated human (hu)p75TNFR transgene in the absence of the endogenous p55TNFR and TNF genes. This ''humanized'' transgenic system allowed us to follow the specific effects of the p75TNFR in mouse CNS in the presence or absence of the p55TNFR and to differentiate between the effects of the two TNFRs in transmission of pathologically relevant effects.
Our results identify a proinflammatory role for p75TNFR when signaling alone in the CNS in vivo and confirm that the p55TNFR plays an exclusive role in mediating TNF-mediated oligodendrocyte apoptosis and primary demyelination. Our data also demonstrate positive cooperation between the two TNFRs during the induction of CNS pathology and attribute disease onset and severity to the level and distribution of TNFR expression in the CNS. This study suggests that differential regulation of the temporal and spatial expression patterns of the individual TNFR in the CNS should play a major role in shaping TNF contribution to a variety of human neurological diseases with diverse characteristics.
Materials and Methods
Transgenic Mice. The glial fibrillary acidic protein (GFAP)-tmTNF transgenic line TgK21 expresses an uncleavable human TNF protein under the control of the GFAP promoter, on the surface of astrocytes and has been described (22, 23) . The transgenic lines TgE1334 and TgE1335 express physiological and 3-fold increased levels of a hup75TNFR transgene, respectively This paper was submitted directly (Track II) to the PNAS office.
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(16). The pattern of expression and regulation of the hup75TNFR transgene is comparable to the endogenous mup75TNFR gene in both lines (16) . Mice deficient in p55TNFR (p55 Ϫ/Ϫ ) or TNF (TNF Ϫ/Ϫ ) were generated by homologous recombination in embryonic stem cells and have also been described (24, 25) . GFAP-tmTNF, TgE1334, and TgE1335 mice were first backcrossed independently onto a p55 Ϫ/Ϫ background and then were crossed to each other. GFAP-tmTNF͞p55 Ϫ/Ϫ and TgE1335͞p55 Ϫ/Ϫ mice were in turn crossed independently onto a TNF Ϫ/Ϫ background and then crossed to each other. Animal maintenance and appropriate crosses between these strains were performed under specific pathogen-free conditions in the animal facility of the Hellenic Pasteur Institute.
Histology and Immunocytochemistry. Mice were transcardially perfused with ice-cold 4% paraformaldehyde in PBS under deep anesthesia. Brain and spinal cord tissues were postfixed by immersion in the same fixative for 3 h at 4°C and embedded in paraffin. Sections (3-to 5-m) were stained with hematoxylin͞ eosin, luxol fast blue͞periodic acid Schiff, or Bielschowsky silver stain according to standard procedures. Immunocytochemistry was performed on paraffin or cryostat sections as described (23) . Primary antibodies were mouse anti-2Ј,3Ј-cyclic nucleotide-3Ј-phosphodiesterase (CNPase, 1͞900, Affiniti Research Products, Nottingham, U.K.), rabbit anti-cow GFAP (1͞200, Dakopatts, Glostrup, Denmark), rabbit anti-mouse p55TNFR (1͞200, Genentech), rabbit anti-mouse p75TNFR (1͞200, Genentech), and rabbit anti-human p75TNFR (provided by M. Grell, University of Stuttgart, Stuttgart, Germany). GFAP-tmTNF transgenic mice spontaneously develop neurological symptoms with hind-limb paralysis during the first month of age and show 100% lethality within the second month of age (22, 23) . Backcrossing onto a p55 Ϫ/Ϫ background (GFAPtmTNF͞p55 Ϫ/Ϫ ) results in complete reversal of this phenotype, whereas absence of p75 TNFR signaling did not alter it, demonstrating that it is mediated by TNF͞p55TNFR signaling (ref. 23 ; Table 1 ). Double GFAP-tmTNF͞hup75 (Tg1335) transgenic mice, in the absence of the p55TNFR, with or without an endogenous TNF gene, develop neurological deficits characterized by tremors, ataxia, and paralysis with 100% penetrance by the fourth month of age and succumb by the sixth month. Tg1335 hup75 mice (16) and TNF Ϫ/Ϫ mice (25) do not independently show any phenotypic abnormalities, suggesting that the observed phenotype is due to activation of the p75TNFR by tmTNF.
p55TNFR and p75TNFR Show Different Localization in the CNS of
Transgenic Mice. To investigate whether differences in the expression of the two TNFRs in the CNS could correlate with the observed effects mediated by the two receptors in tmTNF transgenic mice, immunocytochemical analysis for the two TNFRs was performed on brain and spinal cord tissues. Normal mouse CNS showed low immunoreactivity for the two TNFRs. GFAP-tmTNF brain and spinal cord showed a dramatic increase for both p55TNFR and p75TNFR. The p55TNFR was expressed mainly by glial cells in the parenchyma and by cells of the meninges (Fig. 1A) , whereas the p75TNFR exhibited selective vascular and meningeal localization (Fig. 1B) .
The hup75TNFR Transgene Shows a Similar Pattern of Expression to
the Endogenous mup75TNFR. To confirm that the tissue pattern of hup75TNFR transgene expression is physiologically relevant, we compared the expression pattern of mup75TNFR and hup75TNFR in brain and spinal cord tissues of GFAP-tmTNF͞ hup75 (Tg⌭1335)͞p55 Ϫ/Ϫ mice. Immunocytochemical analysis using antibodies to mup75TNFR or hup75TNFR was performed on serial brain sections of GFAP-tmTNF͞hup75 (Tg⌭1335)͞ p55 Ϫ/Ϫ mice and revealed that the receptors have a comparable pattern of expression that is restricted to the brain vasculature ( Fig. 1 C and D) . To identify the cell type that produces p75TNFR, we performed immunostaining for the endothelial marker intercellular adhesion molecule 1 (ICAM-1) on serial sections. ICAM-1 immunoreactivity was coexpressed with immunoreactivity for the two TNFRs on endothelial cells (Fig. 1E ).
Astrocyte-tmTNF Signaling Through the p75TNFR Induces Inflammatory Ischemia.
To analyze the neuropathological alterations induced by astrocyte-specific tmTNF signaling through the p75TNFR, we performed histopathological analysis of GFAPtmTNF͞hup75 (TgE1335)͞p55 Ϫ/Ϫ mice at different ages using GFAP-tmTNF, GFAP-tmTNF͞p55 Ϫ/Ϫ , and hup75͞p55 Ϫ/Ϫ littermates as controls. At 5 weeks of age, GFAP-tmTNF mice showed inflammation and primary demyelination ( Fig. 2A) , which was completely absent when GFAP-tmTNF mice were backcrossed into a p55 Ϫ/Ϫ background (Fig. 2B ). By contrast, GFAP-tmTNF͞hup75 (TgE1335)͞p55 Ϫ/Ϫ mice showed intact myelin and meningeal inflammation (Fig. 2C) . The absence of demyelination in GFAP-tmTNF͞hup75 (TgE1335)͞ p55 Ϫ/Ϫ mice demonstrates that TNF triggers its effects on oligodendrocytes and myelin specifically through the p55TNFR, but it can trigger inflammation independently through either of the TNFRs. To verify that the inflammatory effects observed were mediated specifically by astrocyte-tmTNF and not endogenous muTNF acting through the hup75 transgene, we backcrossed GFAP-tmTNF͞hup75 (TgE1335)͞p55 Ϫ/Ϫ mice into a TNF Ϫ/Ϫ background. Histopathological analysis showed that GFAP-tmTNF͞hup75 (TgE1335)͞p55 (Fig. 2C) , develop meningeal and parenchymal inflammation with fibrosis by 4 months of age. Taken together, these results show that signaling of tmTNF produced on the surface of astrocytes via the p75TNFR produced by endothelial cells can trigger inflammation and the development of neuropathology in the CNS of transgenic mice. By 5 months of age GFAP-tmTNF͞hup75 (TgE1335)͞p55 Ϫ/Ϫ mice showed ischemic lesions in the spinal cord, cerebellum, and cerebrum. Standard hematoxylin͞eosin staining revealed meningeal fibrosis (Fig. 3A) and inflammation (Fig. 3B) in the spinal cord. Inflammation and fibrosis were observed also in the medulla oblongata (Fig. 3C) . Immunostaining for CNPase revealed that, despite significant inflammation, myelin is largely preserved (Fig. 3D) . Inflammatory lesions progressed into ischemic lesions characterized by tissue necrosis around the inflamed perivascular areas (Fig. 3E) . Within the necrotic areas, secondary loss of myelin is observed as shown with CNPase immunostaining (Fig. 3F) . Staining of serial sections of cerebellum with Bielschowsky silver staining (Fig. 3G) , for axons and neurons, and luxol fast blue͞periodic acid Schiff (Fig. 3H) , for myelin, demonstrated ischemic lesions with secondary axonal and myelin loss. No evidence for primary demyelination, oligodendrocyte apoptosis, or axon loss was observed. Neither GFAP-tmTNF͞p55
control mice showed histopathological abnormalities at this age. These results confirm that TNF-triggered oligodendrocyte apoptosis and primary demyelination are mediated specifically by the p55TNFR, whereas the p75TNFR selectively induces vasculitis with vessel occlusion and subsequent ischemic damage of the tissues.
Differential Expression Levels of p55TNFR and p75TNFR Determine the
Onset and Severity of TNF-Induced Neuropathology. To determine the effect of different expression levels of the p55TNFR and p75TNFR after the development of CNS pathology in tmTNF mice, we generated mice expressing low and high levels of hup75TNFR and reintroduced one or both functional p55TNFR alleles. For the hup75TNFR we compared the hup75TNFR high-expressing TgE1335 and low-expressing TgE1334 lines. For the p55TNFR, we crossed GFAP-tmTNF͞hup75 mice to a homozygous (Ϫ͞Ϫ) or heterozygous (ϩ͞Ϫ) p55TNFR background. The results are summarized in Table 1 . As previously described, GFAP-tmTNF mice with two p55TNFR-deficient alleles develop normally and do not show any histopathological alterations (23) . GFAP-tmTNF mice heterozygous for the p55TNFR-deficient allele (GFAP-tmTNF͞p55 ϩ/Ϫ ) develop ataxia and hind-limb paralysis with a 5-month delay compared with GFAP-tmTNF͞p55 ϩ/ϩ mice (23). The onset of TNF͞ p55TNFR-induced neuropathology therefore depends critically on p55TNFR expression levels. GFA P-tmTNF͞hup75 (TgE1334)͞p55 Ϫ/Ϫ mice develop meningeal inflammation and small perivascular T lymphocyte infiltrates (not shown), showing that physiological levels of the p75TNFR are sufficient to induce inflammation in the CNS when TNF is chronically produced. However, these mice do not develop clinical symptoms. Increased levels of the p75TNFR in GFAP-tmTNF͞hup75 (TgE1335)͞p55 Ϫ/Ϫ mice result in the development of ataxia by 6 months of age and inflammatory ischemia. These results show that the severity of TNF-induced neuropathology depends on the levels of TNFR expression.
The p55TNFR and p75TNFR Act in Cooperation to Induce CNS Pathology. GFAP-tmTNF͞hup75͞p55
ϩ/Ϫ mice are born at low ratios, and the surviving pups show early lethality within the first postnatal week for the high-expressing p75TNFR line (TgE1335) and within the third week for the low-expressing p75TNFR line (TgE1334 ; Table 1 ). When both p55 alleles are present, expression of a functional p75TNFR at either low or high levels leads to embryonic lethality (Table 1) . These results suggest that the two TNFRs in the CNS induce their effects through a cooperative mechanism. Cooperative TNFR signaling accelerates the onset and severity of neuropathology.
Discussion
In this study we investigated the receptor requirements of TNF action during CNS pathogenesis in vivo. We show that the p75TNFR mediates a characteristic proinflammatory effect of tmTNF at the level of the CNS vascular endothelium in humanized tmTNF͞p75TNFR transgenic mice in the absence of the p55TNFR. It was necessary to introduce the hup75TNFR gene, consisting of the entire genomic region and regulatory sequences spanning Ϸ70 kb, into our transgenic system to see the effects of tmTNF͞p75TNFR signaling, because the murine receptor is species-specific and unable to transfer signals from our human TNF transgene (26) . This hup75TNFR transgene is correctly regulated in the TgE1334 and TgE1335 transgenic lines (16) and was shown in this study to be selectively and inducibly expressed by endothelial cells of the CNS vasculature in a pattern parallel to that of the endogenous mup75TNFR gene. Interestingly, the p75TNFR is also selectively expressed by CNS microvascular endothelial cells in experimental cerebral malaria, where it is essential for the development of disease (18) . In our transgenic system, tmTNF͞p75TNFR-triggered effects include ICAM-1 up-regulation on endothelial cells and the recruitment and progressive accumulation of leukocytes at the vasculature, with eventual vascular occlusion and secondary ischemic damage. These effects differ from the previously characterized effects of the same tmTNF transgene through the p55TNFR, specifically oligodendrocyte apoptosis, inflammatory cell recruitment into the parenchyma, and the development of primary demyelinating lesions similar to those in multiple sclerosis (23) . Our findings may have direct relevance for our understanding of human disease pathogenesis. Levels of TNF and the p55TNFR and p75TNFR are positively correlated with relapse in multiple sclerosis (27) , and the p75TNFR is up-regulated on endothelial cells in vascular-mediated pathologies affecting other organs (19) . Locally produced TNF is likely to play a major role both in ischemic stroke (20) and multiple sclerosis (27) , where TNF is undetectable in the plasma. Although the present data strongly support the contribution of astrocyte-produced tmTNF in CNS disease, they of course do not exclude the possibility that soluble TNF can contribute to pathology.
From studies of TNF͞TNFR function in vivo carried out by using animal models of disease with mice carrying targeted gene mutations, it is clear that TNF action in the CNS is multiplex. Several studies point toward an important proinflammatory action of TNF at the level of the brain vasculature. TNF plays an essential role in the initiation of clinical symptoms and in the orchestration of leukocyte trafficking in the CNS parenchyma during experimental autoimmune encephalomyelitis (28) . Blockade of this mechanism by systemically administered anti-TNF agents might account for their successful therapeutic application in experimental autoimmune encephalomyelitis (29) . In experimental cerebral malaria, TNF͞lymphotoxin-␣ and the p75TNFR are essential for the induction of disease after infection by Plasmodium berghei ANKA, which is causally associated with ICAM-1 up-regulation by CNS endothelial cells, mononuclear cell recruitment, and microvascular damage (18, 30) . In experimental cerebral ischemia, TNF expression is rapidly up-regulated and produced by astrocyte end-foot processes lining brain microvessels (2) that are known to contribute to cerebral injury (31) . Therefore, the results of the present study, which show that tmTNF can selectively signal proinflammatory signals through the p75TNFR located on CNS endothelium, may have significant implications for our understanding of disease pathogenesis of a wide-range of unrelated CNS diseases.
Induction of different cellular responses in the CNS by the two TNFRs can be attributed to their differential pattern of expression as well as their induction of distinct intracellular signaling pathways. In vitro studies show that microglia, a primary source of TNF at CNS inflammatory sites, express both p55TNFR and p75TNFR, whereas astrocytes and oligodendrocytes predominantly express p55TNFR (6) , and expression is inducible (1) . In multiple sclerosis lesions, both TNFRs are preferentially expressed on oligodendrocytes (3), but experimental occlusion of the middle cerebral artery results in preferential expression of the TNFR by vascular endothelial cells in the infarcted area (2) . Several studies demonstrate the importance of the p55TNFR in endothelial cell activation, cytotoxicity in the absence of protein synthesis (32), up-regulation of adhesion molecule expression, and leukocyte organ infiltration (33) and cytoskeletal reorganization (34) , whereas the p75TNFR has been assigned an accessory role. Our results now show that the p75TNFR can have an independent role in endothelial cell activation and the upregulation of ICAM-1. It seems that in our transgenic system, inflammatory cells are recruited but unable to damage the brain parenchyma in the absence of the p55TNFR. In the case of chronic signaling, this vasculitic reaction may lead to secondary vessel occlusion, disturbance of microcirculation, and subsequent ischemia. Overall, the variability of TNFR localization in different brain diseases indicates that the stimuli that trigger brain damage determine the spatial pattern of expression of the two TNFRs in the CNS. The different patterns of TNFR expression by glia, neurons, and brain vessels may be critical in determining whether TNF will activate, induce proliferation, or cytotoxicity in these cells and thus determine the final outcome of disease pathogenesis.
TNFRs trimerize after binding by TNF and through activation of distinct intracellular signaling cascades can mediate distinct cellular responses (7) . The p55TNFR recruits TNFR-associated death domain protein (TRADD) followed by TNFR-associated factor 2 (TRAF2) and receptor-interacting protein 1 (RIP1) to drive cell activation and proliferation through activation of nuclear factor B (NF-B) (8) . In the absence of NF-〉 activation, an alternative pathway involving Fas-associated death domain protein (FADD) and procaspase 8 can signal apoptosis (8, 35) . Occupancy of the p75TNFR results in direct TRAF2 recruitment, leading to cell activation and proliferation (8) , although autonomous apoptotic effects of this receptor have been described in T cells and thymocytes (36) (37) (38) (39) . The divergent intracellular signaling pathways of the two TNFRs correlate with our findings that cytotoxic and inflammatory effects of TNF in the CNS of transgenic mice are linked with the p55TNFR, whereas inflammatory effects are linked with the p75TNFR. Interestingly, in our experiments the presence of two functional TNFRs in the CNS exacerbates pathology, and the severity of disease correlates with the level of expression of the TNFR in the CNS. In addition to cooperative proinflammatory effects, the p75TNFR is known to enhance p55TNFR-mediated cytotoxicity (40, 41) . Recent evidence that occupancy of the p75TNFR induces ubiquitination and proteosomal degradation of TRAF2 (42) provides one mechanism by which the p75TNFR might potentiate p55TNFR-mediated apoptosis. Therefore, p75TNFR might enhance p55TNFR cytotoxic effects, and͞or the two TNFRs can have an additive effect in those responses that they trigger via identical pathways such as NF-B activation.
Our study dissociates the roles of the two TNFRs in the CNS in a transgenic system. As we have shown previously, TNF͞ p55TNFR signaling correlates with oligodendrocyte apoptosis and primary demyelination, and here we show that TNF͞p75TNFR signaling is proinflammatory and can induce CNS vascular pathology when TNF is chronically overexpressed. In addition, it reveals a p75TNFR-mediated, p55TNFR-independent mechanism for the induction of vasculitis that can lead to vessel occlusion and secondary ischemia. Recently it was shown that hypoxia-like tissue injury is an important pathogenic mechanism in lesion formation in a subtype of multiple sclerosis and virus encephalitis patients (43) . This process is associated in part with damage and thrombotic occlusion of microvessels (44) . Data on p75TNFR expression in such lesions, however, are still missing. Furthermore, our data show that the outcome and severity of TNF-mediated CNS pathology in transgenic mice depends on the pattern and level of expression of the two TNFRs. It is therefore likely that in human neurological diseases, TNF can induce different cellular responses and pathological manifestations according to the spatial distribution and the up-regulation of its receptors.
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